Sidiropoulos Symeon, Emmanouil-Kalos Alkinoos, Chouzouris Michail, Xenos Panos, Vozikis Athanassios
Department of Public and One Health, University of Thessaly, 43100 Karditsa, Greece.
Hellenic Association of Political Scientists, 10673 Athens, Greece.
Healthcare (Basel). 2025 Jul 16;13(14):1716. doi: 10.3390/healthcare13141716.
: Development Assistance for Health (DAH) plays a vital role in health financing across Sub-Saharan Africa, particularly in tackling communicable diseases such as HIV/AIDS, malaria, and tuberculosis. Despite its importance, the efficiency and equity of DAH allocation remain contested. The study aims to evaluate the cost-effectiveness of DAH in Sub-Saharan Africa from 1995 to 2018, as well as to explore differences in efficiency across diseases and country contexts. : Data were drawn from the Institute for Health Metrics and Evaluation and applied Generalized Cost-Effectiveness Analysis in conjunction with the Gross Domestic Product-based thresholds. Averted Disability-Adjusted Life Years were analyzed across countries and diseases, and countries were categorized by the Human Development Index (HDI) level to assess differential DAH performance. : DAH cost-effectiveness showed similar patterns across HDI groups, with roughly equal proportions of cost-effective and dominated outcomes in both low- and middle-HDI countries. Thirteen countries were identified as very cost-effective, nine as cost-effective, and two as non-cost-effective. Twenty-one countries were dominated, reflecting persistent inefficiencies in aid impact that transcends the various levels of development. : Tailoring DAH allocation to specific disease burdens and development levels enhances its impact. The study underscores the need for targeted investment and a strategic shift toward integrated health system strengthening. Additionally, microinsurance is highlighted as a key mechanism for improving healthcare access and financial protection in low-income settings.
卫生发展援助(DAH)在撒哈拉以南非洲地区的卫生筹资中发挥着至关重要的作用,尤其是在应对诸如艾滋病毒/艾滋病、疟疾和结核病等传染病方面。尽管其重要性,但DAH分配的效率和公平性仍存在争议。该研究旨在评估1995年至2018年期间撒哈拉以南非洲地区DAH的成本效益,并探讨不同疾病和国家背景下的效率差异。数据取自健康指标与评估研究所,并结合基于国内生产总值的阈值应用广义成本效益分析。对各国和各种疾病的避免残疾调整生命年进行了分析,并根据人类发展指数(HDI)水平对国家进行分类,以评估DAH的不同表现。DAH的成本效益在不同HDI组中呈现出相似的模式,在低HDI和中等HDI国家中,具有成本效益和效果不佳的结果所占比例大致相同。确定了13个国家具有很高的成本效益,9个国家具有成本效益,2个国家没有成本效益。21个国家的情况不佳,这反映出援助影响中持续存在的低效率问题,这种低效率超越了不同的发展水平。根据特定的疾病负担和发展水平调整DAH分配可增强其影响。该研究强调了有针对性投资的必要性以及向加强综合卫生系统的战略转变。此外,小额保险被视为改善低收入环境中医疗服务可及性和财务保护的关键机制。